What Is Adlyxin?

1. The Short Answer

Adlyxin is the former U.S. brand name for lixisenatide injection. The DailyMed Medication Guide describes Adlyxin as an injectable prescription medicine that may improve blood sugar control in adults with type 2 diabetes when used with diet and exercise. The FDA label classifies lixisenatide as a GLP-1 receptor agonist.

According to an Optum Rx discontinuation notice, Sanofi announced that Adlyxin would no longer be available in the U.S. market as of January 1, 2023. While the label record remains available for historical reference, Adlyxin is not currently available in U.S. pharmacies.

Adlyxin is the brand name, while lixisenatide is the active ingredient.

For broader class context, see What Is a GLP-1?.

2. What Is Lixisenatide?

Lixisenatide is the active ingredient behind Adlyxin. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, placing it in the same medication class as liraglutide, dulaglutide, and semaglutide.

The 2023 FDA label PDF lists Adlyxin as lixisenatide injection for subcutaneous use and notes its initial U.S. approval in 2016. The Medication Guide states that Adlyxin is not for people with type 1 diabetes and has not been studied in children.

Lixisenatide was a once-daily GLP-1, and should not be confused with liraglutide (the active ingredient in Victoza and Saxenda). Lixisenatide is also the active GLP-1 ingredient in the combination product Soliqua 100/33.

A breakdown of the naming structure:

3. Is Adlyxin Still Available in the U.S.?

Adlyxin is discontinued in the United States. Sanofi announced that Adlyxin would no longer be available in the U.S. market as of January 1, 2023.

The DailyMed label remains online because documentation is retained after a product leaves the market. These labels help explain what the product was, its approved context, and the safety warnings it carried. The presence of a label on DailyMed does not mean the medication can currently be sourced or prescribed.

If a patient’s historical medical records list “Adlyxin,” the practical next step is a clinician or pharmacist consultation regarding current alternatives.

4. How Was Adlyxin Used in Its Label Context?

The DailyMed Medication Guide describes Adlyxin as an injectable prescription medicine for adults with type 2 diabetes, used with diet and exercise to help improve blood sugar control. Its historical label context was once-daily, meal-timed administration.

Unlike newer once-weekly GLP-1 options, Adlyxin was a daily injection tied specifically to meal timing.

The Medication Guide details several contraindications and boundaries, including type 1 diabetes, pancreatitis-history, gastroparesis, slow stomach-emptying, and pancreatitis-warning language.

These details highlight why historical label records remain relevant.

5. Adlyxin vs Soliqua 100/33

Adlyxin and Soliqua 100/33 both utilize lixisenatide, but they are different products. Adlyxin was lixisenatide alone. The current DailyMed Soliqua 100/33 label describes Soliqua 100/33 as an insulin glargine and lixisenatide injection.

Soliqua is a fixed-ratio combination product containing basal insulin and a GLP-1. Adlyxin was a standalone GLP-1.

While the standalone Adlyxin brand left the U.S. market, lixisenatide remains available as a component of Soliqua.

For more on the combination product, see What Is Soliqua?.

6. Adlyxin, Lyxumia, and International Names

Adlyxin was the U.S. brand name, while Lyxumia was the European brand name for lixisenatide.

The European Medicines Agency Lyxumia record states that the European Commission withdrew the marketing authorisation for Lyxumia in the European Union on December 18, 2025, at Sanofi’s request following a commercial decision to permanently discontinue the product. The EMA notes Lyxumia was originally granted EU marketing authorisation on February 1, 2013.

As of May 6, 2026, “Adlyxin” refers to the former U.S. brand, and “Lyxumia” refers to the former European brand. Lixisenatide is the active ingredient for both. Drug brand names often vary by region, while the active molecule name remains consistent internationally.

7. How Is Adlyxin Different From Ozempic, Trulicity, and Mounjaro?

Adlyxin, Ozempic, Trulicity, and Mounjaro are often grouped in GLP-1 discussions, but they use different active ingredients and have different receptor profiles.

DailyMed labels classify Adlyxin (lixisenatide), Ozempic (semaglutide), and Trulicity (dulaglutide) as GLP-1 receptor agonists. The Mounjaro (tirzepatide) label describes it as a dual GIP and GLP-1 receptor agonist.

Availability marks the primary functional difference today. Adlyxin is discontinued in the U.S. as a standalone product. Ozempic, Trulicity, and Mounjaro maintain current U.S. labels and market availability.

For related explainers, see What Is Ozempic?, What Is Trulicity?, and What Is Mounjaro?.

8. Why Does Lixisenatide Show Up in Parkinson’s Research?

Lixisenatide occasionally appears outside of diabetes contexts due to research into GLP-1 receptor agonists for neurodegenerative diseases. A 2024 New England Journal of Medicine trial studied lixisenatide in 156 participants with early Parkinson’s disease. The study was a phase 2, randomized, double-blind, and placebo-controlled trial.

This trial does not mean Adlyxin is an approved Parkinson’s medication or that lixisenatide has a U.S. label for the condition. It indicates that researchers tested the lixisenatide molecule in a defined clinical study and reported the results.

References to lixisenatide in Parkinson’s research refer to the active ingredient under study, not a revival of the discontinued Adlyxin brand.

9. Documenting Adlyxin in Medication Records

When maintaining a medication log or reviewing historical charts, recording Adlyxin with separate fields for brand, active ingredient, label context, and availability prevents confusion.

A clear entry format:

This structure maintains factual accuracy and avoids confusing the discontinued brand name, the active molecule, and current combination products.

10. What Adlyxin Means Now

Adlyxin serves primarily as historical context for the standalone U.S. lixisenatide brand. The label remains a useful resource for understanding the specific molecule, its once-daily GLP-1 designation, its type 2 diabetes indication, and its safety parameters.

Evaluating GLP-1 medications requires distinguishing between the specific brand, the active molecule, the approved label context, and its current availability status. Adlyxin demonstrates that the broader GLP-1 category includes both current weekly medications and discontinued daily options.

11. Adlyxin FAQ

• What is Adlyxin in simple terms?

  Adlyxin is the Sanofi brand name for lixisenatide injection. The DailyMed Medication Guide describes it as an injectable prescription medicine that may improve blood sugar control in adults with type 2 diabetes when used with diet and exercise.

• Is Adlyxin still available in the United States?

  Sanofi announced that Adlyxin would no longer be available in the U.S. market as of January 1, 2023. DailyMed still has label and Medication Guide records, which are useful for historical and label-reference purposes.

• Is Adlyxin the same as lixisenatide?

  No. Lixisenatide is the active ingredient. Adlyxin was a U.S. brand name for lixisenatide injection.

• Is Adlyxin the same as Soliqua?

  No. Adlyxin was lixisenatide alone. Soliqua 100/33 is a different product that combines insulin glargine and lixisenatide in a fixed-ratio injection, according to the current DailyMed Soliqua label.

• Was lixisenatide studied for Parkinson's disease?

  Yes. A 2024 New England Journal of Medicine phase 2 trial studied lixisenatide in 156 people with early Parkinson's disease. That research does not make Adlyxin an approved Parkinson's treatment.

12. Sources